利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.024 秒)

    Therapeutic morpholino-substituted compounds
    1.
    发明授权
    Therapeutic morpholino-substituted compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US06977255B2

    公开(公告)日：2005-12-20

    申请号：US10181485

    申请日：2001-01-24

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yap ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yap ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K9/02 ,  A61K9/08 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/5377 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/04 ,  A61P37/06 ,  A61P43/00 ,  C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04 ,  A61K31/352

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 包括诸如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌等癌症的肿瘤，以及与无序白细胞功能相关的疾病，例如自身免疫性和炎性疾病。

    Compounds for therapy and diagnosis
    2.
    发明授权
    Compounds for therapy and diagnosis 有权
    用于治疗和诊断的化合物

    公开(公告)号：US08389506B2

    公开(公告)日：2013-03-05

    申请号：US12746382

    申请日：2008-12-05

    申请人： Kevin Jeffrey Barnham ,  Vijaya Kenche

    发明人： Kevin Jeffrey Barnham ,  Vijaya Kenche

    IPC分类号： A61K31/555 ,  C07F15/00

    CPC分类号： C07D401/04 ,  A61K49/0017 ,  A61K51/0453 ,  A61K51/0478 ,  C07F15/0093

    摘要： The present invention relates to a transition metal complex represented by Formula (I) or salts thereof, or to a ligand represented by Formula (H) or salts thereof, wherein X represents a transition metal, preferably Pt, and methods for their use and preparation. In particular, the invention relates to compounds which may possess useful therapeutic activity in treating amyloid diseases, and in particular, Alzheimer's disease. The invention also relates to the use of these compounds in methods of therapy, and diagnosis, and the manufacture of medicaments as well as compositions containing these compounds.

    摘要翻译： 本发明涉及由式（I）表示的过渡金属络合物或其盐，或由式（H）表示的配体或其盐，其中X表示过渡金属，优选Pt，及其用途及制备方法 。 特别地，本发明涉及在治疗淀粉样蛋白病，特别是阿尔茨海默病方面具有有用治疗活性的化合物。 本发明还涉及这些化合物在治疗，诊断和制备药物以及含有这些化合物的组合物的方法中的用途。

    Therapeutic Morpholino-Substituted Compounds
    3.
    发明申请
    Therapeutic Morpholino-Substituted Compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US20080206312A1

    公开(公告)日：2008-08-28

    申请号：US12019061

    申请日：2008-01-24

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K31/5377 ,  C07D413/04 ,  A61K9/12 ,  A61K47/06 ,  A61P9/00 ,  A61P11/00 ,  A61P35/04 ,  A61P7/00

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病; 肿瘤包括癌症，如胶质瘤，前列腺癌，小细胞肺癌和乳腺癌; 以及与无序白细胞功能相关的疾病，如自身免疫性疾病和炎性疾病。

    Therapeutic morpholino-substituted compounds
    4.
    发明申请
    Therapeutic morpholino-substituted compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US20050085471A1

    公开(公告)日：2005-04-21

    申请号：US10961062

    申请日：2004-10-12

    申请人： Alan Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K9/02 ,  A61K9/08 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K31/5377 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/04 ,  A61P37/06 ,  A61P43/00 ,  C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04 ,  C07D413/04

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病，包括癌症如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌的肿瘤，以及与无序白细胞功能如自身免疫性和炎性疾病相关的疾病。

    Therapeutic Morpholino-Substituted Compounds
    7.
    发明申请
    Therapeutic Morpholino-Substituted Compounds 审中-公开

    公开(公告)号：US20080312233A1

    公开(公告)日：2008-12-18

    申请号：US12115563

    申请日：2008-05-06

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K31/5377 ,  A61P11/00 ,  A61P9/00

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    Therapeutic morpholino-substituted compounds
    8.
    发明授权
    Therapeutic morpholino-substituted compounds 失效
    治疗性吗啉取代的化合物

    公开(公告)号：US07405211B2

    公开(公告)日：2008-07-29

    申请号：US10961062

    申请日：2004-10-12

    申请人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    发明人： Alan D. Robertson ,  Shaun Jackson ,  Vijaya Kenche ,  Cindy Yaip ,  Hishani Parbaharan ,  Phil Thompson

    IPC分类号： A61K31/5377 ,  C07D413/04

    CPC分类号： C07D215/38 ,  C07D311/22 ,  C07D311/58 ,  C07D311/64 ,  C07D471/04

    摘要： Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

    摘要翻译： 吗啉取代的吡啶并嘧啶，喹诺酮和苯并吡喃酮衍生物抑制磷酸肌醇（PI）3-激酶，其是调节血小板粘附过程的酶。 因此，所讨论的化合物具有抗血栓形成活性以及其它药物性质。 所要求的化合物由式（I），（II）和（III）表示。 PI 3激酶产生在血液流动条件下刺激血小板粘附的3-磷酸化PI第二信使。 因为血小板粘附是形成血栓的必要步骤，所以这些条件下这些PI3-激酶化合物的抑制可抑制或预防血栓形成。 该化合物可用于治疗PI 3激酶依赖性疾病，包括心血管疾病如冠状动脉闭塞，中风，急性冠状动脉综合征，急性心肌梗塞，血管再狭窄，动脉粥样硬化和不稳定型心绞痛; 呼吸系统疾病如哮喘，慢性阻塞性肺疾病（COPD）和支气管炎; 炎症性疾病，包括癌症如神经胶质瘤，前列腺癌，小细胞肺癌和乳腺癌的肿瘤，以及与无序白细胞功能如自身免疫性和炎性疾病相关的疾病。

    COMPOUNDS FOR THERAPY AND DIAGNOSIS
    10.
    发明申请
    COMPOUNDS FOR THERAPY AND DIAGNOSIS 有权
    治疗和诊断的化合物

    公开(公告)号：US20110110850A1

    公开(公告)日：2011-05-12

    申请号：US12746382

    申请日：2008-12-05

    申请人： Kevin Jeffrey Barnham ,  Vijaya Kenche

    发明人： Kevin Jeffrey Barnham ,  Vijaya Kenche

    IPC分类号： A61K51/00 ,  C07F15/00 ,  C07D401/10 ,  A61K31/555 ,  A61K49/00 ,  A61P43/00 ,  A61K49/06

    CPC分类号： C07D401/04 ,  A61K49/0017 ,  A61K51/0453 ,  A61K51/0478 ,  C07F15/0093

    摘要： The present invention relates to a transition metal complex represented by Formula (I) or salts thereof, or to a ligand represented by Formula (H) or salts thereof, wherein X represents a transition metal, preferably Pt, and methods for their use and preparation. In particular, the invention relates to compounds which may possess useful therapeutic activity in treating amyloid diseases, and in particular, Alzheimer's disease. The invention also relates to the use of these compounds in methods of therapy, and diagnosis, and the manufacture of medicaments as well as compositions containing these compounds.

    摘要翻译： 本发明涉及由式（I）表示的过渡金属络合物或其盐，或由式（H）表示的配体或其盐，其中X表示过渡金属，优选Pt，及其用途及制备方法 。 特别地，本发明涉及在治疗淀粉样蛋白病，特别是阿尔茨海默病方面具有有用治疗活性的化合物。 本发明还涉及这些化合物在治疗，诊断和制备药物以及含有这些化合物的组合物的方法中的用途。